Discover top-quality products tailored for scientific and medical research. Request a personalized quote today
to enhance your projects.
| Product Code | MTC-TT |
| Species | Human |
| Cat.No | ABC-TC484S |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Thyroid |
| Storage | Liquid Nitrogen |
| Product Type | Human Thyroid Cancer Cell Lines |
The TT cell line is a human medullary thyroid carcinoma (MTC) model derived from a needle biopsy of a 77-year-old Caucasian female patient. This adherent cell line exhibits epithelial-like morphology and harbors an aneuploid karyotype with modal chromosome number of 40. The cells are characterized by the high expression of calcitonin and carcinoembryonic antigen (CEA), along with the production of multiple peptide hormones including adrenocorticotropic hormone (ACTH), neurotensin, enkephalin, parathyroid hormone-related peptide (PTHrP), gastrin-releasing peptide (GRP) and serotonin. TT cells retain tumorigenic potential, forming subcutaneous tumors in nude mice, making them a reliable in vivo model for medullary thyroid carcinoma.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $100 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
The TT cell line serves as a valuable tool for studying medullary thyroid carcinoma (MTC), particularly in preclinical investigations aimed at understanding tumor behavior and evaluating novel therapeutics. It plays a crucial role in conducting 3D culture models to better simulate the tumor microenvironment, enabling studies on tumor invasion, migration, proliferation, apoptosis, cell cycle dynamics, and miRNA regulation. TT cells provide a robust platform for evaluating anti-cancer compounds and elucidating molecular mechanisms associated with MTC pathogenesis and treatment resistance, thereby contributing to the development of targeted treatments for this specific malignancy.
